60 Degrees Pharmaceuticals’ (SXTP) “Neutral” Rating Reaffirmed at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of 60 Degrees Pharmaceuticals (NASDAQ:SXTP) in a report published on Friday morning, Benzinga reports.

60 Degrees Pharmaceuticals Trading Up 0.7 %

Shares of SXTP opened at $1.39 on Friday. The stock has a 50 day moving average of $0.76 and a 200 day moving average of $0.28. 60 Degrees Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $18.36. The company has a market capitalization of $16.97 million, a price-to-earnings ratio of -1.34 and a beta of 4.61.

60 Degrees Pharmaceuticals (NASDAQ:SXTP) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($4.23) EPS for the quarter, missing analysts’ consensus estimates of ($2.79) by ($1.44). The firm had revenue of $0.13 million during the quarter, compared to analysts’ expectations of $0.11 million. As a group, equities research analysts predict that 60 Degrees Pharmaceuticals will post -5.43 earnings per share for the current year.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.